- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Gubra A/S: Gubra collaboration partner Hemab announces first participant dosed in Phase 1 clinical trial of HMB-003, an investigational therapy for the management of heavy menstrual bleeding | 152 | GlobeNewswire (Europe) | Today, Gubra announced that its partner Hemab Therapeutics has dosed the first healthy volunteer in its Phase 1 clinical trial evaluating HMB-003, an investigational therapy for the management of heavy... ► Artikel lesen | |
| Do | Hemab Therapeutics, Inc.: Hemab Therapeutics Announces First Participant Dosed in Phase 1 Clinical Trial of HMB-003, an Investigational Therapy for the Management of Heavy Menstrual Bleeding | 144 | GlobeNewswire (Europe) | Heavy menstrual bleeding is reported in approximately 1 in 3 reproductive-aged women, according to the American College of Obstetricians and Gynecologists, with approximately 23 million seeking care... ► Artikel lesen | |
| 14.08. | Biotech Stocks At 52-Week Highs - Park Dental Partners +10%, Aveanna Healthcare +24%, Candel Therapeutics +10% on Q2 Reports, Labcorp Holdings, Hemab Therapeutics | 1.092 | AFX News | LONDON (dpa-AFX) - The following biotech stocks reached 52-week highs on August 13, 2026, driven by key catalysts such as positive quarterly reports and the issuance of increased guidance figures.Park... ► Artikel lesen | |
| 12.08. | H.C. Wainwright hebt Kursziel für Hemab Therapeutics auf 60 US-Dollar an | 2 | Investing.com Deutsch | ||
| 11.08. | Hemab Therapeutics Holdings, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 07.08. | Biotech Stocks At 52-Week Highs - Delcath Systems +22% On Q2 Results, Alto Neuroscience, Hemab Therapeutics, Monopar Therapeutics, Nurix Therapeutics | 1.032 | AFX News | SOUTH SAN FRANCISCO (dpa-AFX) - The following biotech stocks reached 52-week highs on August 7, 2026, driven by key catalysts such as positive quarterly reports or upcoming conference participation.... ► Artikel lesen | |
| HEMAB THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 14.07. | Hemab präsentiert Phase-2-Daten für Sutacimig und plant Phase-3-Studie | 2 | Investing.com Deutsch | ||
| 14.07. | Hemab presents phase 2 data for sutacimig, plans phase 3 trial | 1 | Investing.com | ||
| 14.07. | Hemab Therapeutics, Inc.: Hemab Therapeutics Presents Clinical and Preclinical Data from Sutacimig in Glanzmann Thrombasthenia and Factor VII Deficiency at the ISTH 2026 Congress | 1 | GlobeNewswire (USA) | ||
| 13.07. | Hemab Advances Bleeding Disorder Pipeline | 3 | Benzinga.com | ||
| 13.07. | Hemab Therapeutics stock price target raised to $52 by H.C. Wainwright on trial data | 1 | Investing.com | ||
| 12.07. | Hemab Therapeutics, Inc.: Hemab Therapeutics Presents New Clinical Data from HMB-002 in Von Willebrand Disease and Introduces HMB-003 for Heavy Menstrual Bleeding at the ISTH 2026 Congress | 3 | GlobeNewswire (USA) | ||
| 10.07. | Gubra A/S: Gubra collaboration partner Hemab to present preclinical results for HMB-003, a potential treatment for multiple bleeding disorders, at the ISTH 2026 Congress | 411 | GlobeNewswire (Europe) | Copenhagen, July 10, 2026: Gubra's collaboration partner Hemab will present preclinical results from the HMB-003 program on July 11, 2026, at the ISTH Congress in Paris.
The preclinical data show that... ► Artikel lesen | |
| 26.06. | Hemab Therapeutics: Positive Studiendaten und Pipeline-Erweiterung treiben Aktie an | 1 | Investing.com Deutsch | ||
| 26.06. | Hemab announces clinical updates across bleeding disorder pipeline | 2 | Investing.com | ||
| 26.06. | Hemab Therapeutics, Inc.: Hemab Therapeutics to Present Clinical and Preclinical Data from Multiple Blood Coagulation Programs at the ISTH 2026 Congress | 1 | GlobeNewswire (USA) | ||
| 17.06. | H.C. Wainwright initiates Hemab Therapeutics stock coverage with buy rating | 3 | Investing.com | ||
| 26.05. | Wedbush initiates Hemab Therapeutics stock with outperform rating | 1 | Investing.com | ||
| 26.05. | Jefferies stuft Hemab Therapeutics mit "Buy" ein - Hohes Potenzial bei seltenen Blutgerinnungsstörungen | 1 | Investing.com Deutsch | ||
| 26.05. | Jefferies initiates Hemab Therapeutics stock with buy rating on rare bleeding disorder potential | 1 | Investing.com |
1 2 3 Weiter >>
43 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| AMGEN | 335,15 | +1,30 % | Amgen-Aktie: Kann man jetzt schon ein Schnäppchen machen? | Es ist eine bislang miserable Handelswoche für die Amgen-Aktie. Seit Wochenbeginn ging es mit dem Kurs des US-Biopharmariesen um über -13% bergab. Was zieht Amgen dieser Tage in den Kurskeller und können... ► Artikel lesen | |
| REGENERON PHARMACEUTICALS | 685,10 | +0,53 % | Regeneron auf Morgan Stanley Konferenz: Wachstum stützt sich auf Dupixent | ||
| CELLDEX THERAPEUTICS | 33,440 | +0,57 % | Celldex Therapeutics, Inc.: Celldex Reports Results from Phase 2 Study of Barzolvolimab in Prurigo Nodularis | Study did not meet key efficacy objectives Favorable safety profile consistent with prior studies, including with new 450mg loading dose and up to 300mgQ4W regimenProfound systemic mast cell depletion... ► Artikel lesen | |
| ARGENX | 865,60 | +0,14 % | JEFFERIES stuft Argenx auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Argenx mit einem Kursziel von 1215 US-Dollar auf "Buy" belassen. Im Auge behalten werden sollte insbesondere die Studie... ► Artikel lesen | |
| REVOLUTION MEDICINES | 165,20 | -3,65 % | Revolution Medicines, Inc.: Revolution Medicines Announces U.S. FDA Breakthrough Therapy Designation for RASONQUE (daraxonrasib) in Combination with Chemotherapy for First Line Metastatic Pancreatic Cancer | Company receives third Breakthrough Therapy Designation for RASONQUE and fifth across its portfolio of RAS(ON) inhibitors, further highlighting its differentiated strategy for developing innovative... ► Artikel lesen | |
| INSMED | 106,84 | -1,09 % | The Fund Exited Insmed (INSM) After the Investment Thesis Played Out | ||
| ORUKA THERAPEUTICS | 79,00 | -7,60 % | Oruka Therapeutics, Inc.: Oruka Therapeutics Appoints Todd Edwards as Chief Commercial Officer | MENLO PARK, Calif., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. ("Oruka") (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard... ► Artikel lesen | |
| KRYSTAL BIOTECH | 292,80 | -0,71 % | Krystal Biotech, Inc.: Krystal Biotech Announces Second Quarter 2026 Financial and Operating Results | $119.2 million in 2Q VYJUVEK global revenue and $965.9 million since launch Multiple clinical data readouts in 2H 2026 On track for VYJUVEK launches in Spain and Italy later this year Strong balance... ► Artikel lesen | |
| ULTRAGENYX | 12,900 | +2,06 % | Abeona Therapeutics Inc.: Abeona Therapeutics Congratulates Ultragenyx on U.S. FDA Approval of FAYUVI Gene Therapy for Sanfilippo Syndrome Type A (MPS IIIA) | - FDA approval represents a monumental milestone for patients with MPS IIIA and validates Abeona's foundational R&D and clinical development efforts - - Ultragenyx successfully brought a life-changing... ► Artikel lesen | |
| SCHOLAR ROCK | 42,500 | -0,47 % | Scholar Rock downgraded at Barclays despite FDA approval of SMA therapy | ||
| PALVELLA THERAPEUTICS | 131,00 | -2,24 % | Palvella Therapeutics Inc.: Palvella Therapeutics Appoints James R. Treat, M.D., Nationally Recognized Pediatric Dermatologist as Chief Medical Officer | Brings expertise in cutaneous vascular anomalies, including microcystic lymphatic malformations, venous malformations and angiokeratomas Leader in pediatric dermatology with nearly 20 years of distinguished... ► Artikel lesen | |
| IMMUNOCORE | 28,000 | -0,71 % | Immunocore Holdings plc: Immunocore announces achievement of target enrollment in registrational TEBE-AM trial with KIMMTRAK (tebentafusp) in previously treated advanced melanoma | Immunocore announces achievement of target enrollment in registrational TEBE-AM trial with KIMMTRAK- (tebentafusp) in previously treated advanced melanoma Topline overall survival data expected as... ► Artikel lesen | |
| VAXCYTE | 50,000 | -5,66 % | XETR NEW INSTRUMENTS AVAILABLE ON XETRA - 04.06.2026 | Folgende Wertpapiere werden in den Handel an folgenden Handelsplätzen (MIC Code) im Quotation Board an der Frankfurter Wertpapierbörse (FWB) aufgenommen. Die Notierung an anderen Handelsplätzen im Quotation... ► Artikel lesen | |
| RELAY THERAPEUTICS | 18,850 | -1,72 % | Relay Therapeutics auf Morgan Stanley Konferenz: Mehrere Entwicklungschancen mit einem Wirkstoff | ||
| VERA THERAPEUTICS | 34,010 | -0,76 % | Vera Therapeutics Announces TRUTAKNA (atacicept-vymj) Stabilized eGFR and Prevented Kidney Disease Progression Through Two Years in ORIGIN 3 Final Efficacy Analysis in IgA Nephropathy | TRUTAKNA, the first and only FDA-approved BAFF and APRIL inhibitor, met all prespecified endpoints, including unprecedented placebo-adjusted estimated glomerular filtration rate (eGFR) and composite... ► Artikel lesen |
HEMAB THERAPEUTICS HOLDINGS INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von -0,030 (-0,07 %) liegt der Kurs bei 41,190 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu HEMAB THERAPEUTICS HOLDINGS INC finden Sie auf Wallstreet Online.